Leaving no one behind with immunisation

Gavi, the Vaccine Alliance is a public-private partnership that helps vaccinate more than half the world’s children against some of the world's deadliest diseases.


About us Explore our Progress Report

Latest VaccinesWork features

View more

Home-coming healthcare: Malawians returning from South Africa met by health teams

Fleeing xenophobic violence in South Africa, thousands of travel-stressed Malawian families arrived home to health screenings, nutritional supplementation, catch-up jabs and a link-up to their new local clinic.

Eight numbers that explain the impact of Gavi, the Vaccine Alliance in 2025

In the time it takes you to read this article, Gavi-supported vaccines will have saved 25 lives.

Dogs, devils, clams and catfish: When cancer is contagious

In a handful of animals, tumors can be transmitted like infectious diseases or parasites, defying science’s tidy definitions.

VaccinesWork is an award-winning digital platform hosted by Gavi, covering news, features and explainers from every corner of global health and immunisation.

The Gavi Leap

The Gavi Leap

The Gavi Leap is the most ambitious reform agenda in global health, offering a blueprint for broader reform of the health and development architecture. Learn more about how Leap principles, such as country ownership, radical simplification and innovation, are already having a tangible impact on how immunisation is delivered in Gavi-supported countries.

The Gavi Leap

Our work

A mother with her child in Tanzania. Credit: Doune Porter

Vaccine portfolio

Gavi supports vaccines against 20 infectious diseases, including Ebola, malaria, mpox and rabies.

View our vaccines

A health worker in Tanzania. Credit: Gavi/2012/P Rudden

Health systems support

Strong health and immunisation systems are vital to deliver vaccines to all the children who need them.

Learn more

A health worker carrying vaccines in a cold box in Somalia. Credit: Gavi

Civil society support

We provide grants for civil society organisations (CSOs) working to reach zero-dose children and missed communities with vaccines.

Our work with CSOs

Gavi/2024/Mohamed Abdihakim Ali

Shaping vaccine markets

Working to improve the health of markets for vaccines and other immunisation products.

Learn more

Latest Gavi news releases

View all

Vaccines deliver over US$ 30 billion in economic benefits for lower-income countries in 2025

Gavi-supported immunisation generated more than US$ 30 billion in economic benefits in 2025, through lower healthcare costs and healthier, more productive populations.

Made in Africa: New measles rapid diagnostic tests mark breakthrough for vaccination efforts

First-of-their-kind rapid measles diagnostic tests will support targeted vaccination during outbreaks and identification of priorities for preventive vaccination efforts.

The Vaccine Alliance

The Vaccine Alliance

Gavi draws on the skills of a variety of partners, combining the technical expertise of the development community with the business know-how of the private sector.

The Vaccine Alliance

Gavi 6.0 funding guidelines

Newly released funding guidelines outline the scope of Gavi’s vaccine and cash support for the 2026–2030 strategic period (Gavi 6.0), explain how countries should plan and prioritise their immunisation programmes within this support, clarify the requirements for the Gavi 6.0 country application and describe how to access other forms of assistance such as outbreak and emergency support.

Access the guidelines

World Map

Partner countries

Partner countries

Since its inception in 2000, Gavi has helped to immunise a whole generation – over 1.2 billion children – and prevented more than 20.6 million future deaths, helping to halve child mortality in 78 lower‑income countries.

Our donors

Our donors

As a public-private partnership, Gavi is funded by governments, foundations, institutions, organisations, corporations and private individuals.

Global Summit 2025

>1.3 billion children vaccinated through routine programmes
>23 million future deaths averted
19 countries fully self-financing
>308 US$ billion in economic benefits for countries
2.4 billion vaccinations through preventive vaccination campaigns